Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06942520 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
A Phase 2 study of Diabetic Macular Edema, sponsored by Sierra Eye Associates.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT06942520: Recruiting Phase 2 study of Diabetic Macular Edema, sponsored by Sierra Eye Associates.
NCT06942520 is a Phase 2 study of Diabetic Macular Edema that is actively recruiting participants, run by Sierra Eye Associates. The registered enrollment target is 18 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06942520, a Phase 2 study of Diabetic Macular Edema, is actively recruiting participants, sponsored by Sierra Eye Associates.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase 2 open label, randomized, active controlled, dose-ranging trial in adults with Center Involved - Diabetic Macular Edema (CI - DME)
Primary Outcome
To evaluate the effect of RGX-314 on BCVA at Week 52
Conditions Studied
Interventions
- GENETIC RGX-314 Dose 1
- GENETIC RGX-314 Dose 2
- BIOLOGICAL Aflibercept (2.0 mg)
Study Locations (1)
Nevada
- Sierra Eye Associates - Reno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-03-18 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT06942520 shows while recruiting
NCT06942520 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 3 interventions - of which RGX-314 Dose 1 is the first listed.
NCT06942520 reports a single indexed study location in Nevada.
Frequently Asked Questions
What is clinical trial NCT06942520 about?
NCT06942520 is a clinical study titled "Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)". Phase 2 open label, randomized, active controlled, dose-ranging trial in adults with Center Involved - Diabetic Macular Edema (CI - DME)
What is the current status of trial NCT06942520?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2025-03-18. Estimated completion is 2027-12.
What conditions does trial NCT06942520 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT06942520?
The interventions under investigation include: RGX-314 Dose 1 (GENETIC), RGX-314 Dose 2 (GENETIC), Aflibercept (2.0 mg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06942520?
This trial is sponsored by Sierra Eye Associates, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06942520 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06942520's enrollment target sits among peer trials
18 57th of 63 higher than 7 of 63 other Diabetic Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
ACTIVE NOT RECRUITING · Phase 2
-
4D-150 in Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Tonabersat for DME
ACTIVE NOT RECRUITING · Phase 2
-
Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
COMPLETED · Phase 2
-
Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI